The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling-Reference-Cited by-同舟云学术

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling

Published:2013-03-18 Issue:3 Volume:8 Page:e59588
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Desai Brijal M.,Villanueva Jessie,Nguyen Thierry-Thien K.,Lioni Mercedes,Xiao Min,Kong Jun,Krepler Clemens,Vultur Adina,Flaherty Keith T.,Nathanson Katherine L.,Smalley Keiran S. M.,Herlyn Meenhard

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference51 articles.

1. BRAF and RAS mutations in human lung cancer and melanoma;MS Brose;Cancer Research,2002

2. Mutations of the BRAF gene in human cancer;H Davies;Nature,2002

3. A Landscape of Driver Mutations in Melanoma;E Hodis;Cell,2012

4. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H (2012) Melanoma: New Insights and New Therapies. The Journal of investigative dermatology.

5. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib;JA Sosman;New England Journal of Medicine,2012

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity;Bioorganic Chemistry;2024-06

2. Exploring new quinazolin‐4(3H)‐one derivatives as CDK2 inhibitors: Design, synthesis, and anticancer evaluation;Drug Development Research;2024-02-28

3. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study;Cells;2024-02-20

4. Cyclin-dependent kinase 2 (CDK2);Metalloenzymes;2024

5. Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents;RSC Advances;2023